Cargando…

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study †

SIMPLE SUMMARY: In this manuscript, we present a statistical model for reliable and early prediction of treatment failure in patients with diffuse large B-cell lymphoma. The model combines measurable parameters—namely, the metabolic tumor volume and the metabolic heterogeneity, from baseline PET/CT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genta, Sofia, Ghilardi, Guido, Cascione, Luciano, Juskevicius, Darius, Tzankov, Alexandar, Schär, Sämi, Milan, Lisa, Pirosa, Maria Cristina, Esposito, Fabiana, Ruberto, Teresa, Giovanella, Luca, Hayoz, Stefanie, Mamot, Christoph, Dirnhofer, Stefan, Zucca, Emanuele, Ceriani, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870624/ https://www.ncbi.nlm.nih.gov/pubmed/35205765 http://dx.doi.org/10.3390/cancers14041018

Ejemplares similares

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
por: Juskevicius, Darius, et al.
Publicado: (2017)

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study
por: Tzankov, Alexandar, et al.
Publicado: (2015)

Genetic background and evolution of relapses in aggressive B-cell lymphomas
por: Juskevicius, Darius, et al.
Publicado: (2017)

Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin
por: Vela, Visar, et al.
Publicado: (2021)

Genomic Landscape of Hodgkin Lymphoma
por: Brune, Magdalena M., et al.
Publicado: (2021)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022)

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells
por: Burkhard, Regula, et al.
Publicado: (2019)

Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma
por: Paone, Gaetano, et al.
Publicado: (2021)

Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
por: Hayoz, Stefanie, et al.
Publicado: (2023)

(99m)Tc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities
por: Giovanella, Luca, et al.
Publicado: (2019)

Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas
por: Tzankov, Alexandar, et al.
Publicado: (2007)

External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26
por: Herrmann, Evelyn, et al.
Publicado: (2017)

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
por: Brune, Magdalena M., et al.
Publicado: (2021)

High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations
por: Pillonel, V., et al.
Publicado: (2018)

Lymph Node Thyroglobulin Measurement in Diagnosis of Neck Metastases of Differentiated Thyroid Carcinoma
por: Giovanella, Luca, et al.
Publicado: (2011)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
por: Novak, Urban, et al.
Publicado: (2023)

H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas
por: Brune, Magdalena M., et al.
Publicado: (2022)

1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
por: Joerger, M., et al.
Publicado: (2021)

The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis
por: Giovanella, Luca, et al.
Publicado: (2022)

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
por: Panje, Cédric M., et al.
Publicado: (2019)

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
por: Joerger, Markus, et al.
Publicado: (2022)

Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94)
por: Ghadjar, Pirus, et al.
Publicado: (2015)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Aggressive Histological Subtypes of Thyroid Cancer: An Overview
por: Treglia, Giorgio, et al.
Publicado: (2013)

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
por: Mark, Michael, et al.
Publicado: (2019)

Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
por: Obermann, Ellen C, et al.
Publicado: (2005)

(18)F-FDG-PET/CT Imaging in Advanced Glottic Cancer: A Tool for Clinical Decision in Comparison with Conventional Imaging
por: Paone, G., et al.
Publicado: (2019)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
por: Drexler, Beatrice, et al.
Publicado: (2019)

Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
por: Treglia, Giorgio, et al.
Publicado: (2019)

Radiomics analysis improves (18)FDG PET/CT-based risk stratification of cytologically indeterminate thyroid nodules
por: Giovanella, Luca, et al.
Publicado: (2021)

EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
por: Li, Yong, et al.
Publicado: (2022)

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas
por: Muenst, S., et al.
Publicado: (2010)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
por: Joerger, M., et al.
Publicado: (2020)

The Role of Structural Extracellular Matrix Proteins in Urothelial Bladder Cancer (Review)
por: Brunner, Andrea, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_jga0r5iljhs4ejqgtenogkjgg3